Nicholas T. Pinchuk, Chairman, President and CEO of Snap-on Incorporated (NYSE:SNA), filed a Form 4 on August 19, 2026, reporting the exercise of 33,750 stock options and the sale of 22,889 shares of common stock on August 18, 2026, pursuant to a Rule 10b5-1 …
Kyle C. Badger, SVP, General Counsel and Secretary of Agilysys Inc (NASDAQ:AGYS), filed a Form 4 on August 19, 2026, disclosing the sale of 8,400 shares of common stock on August 18, 2026.
William David Wood III, Chief Financial Officer of Agilysys, Inc. (NASDAQ:AGYS), filed a Form 4 on August 19, 2026, reporting the sale of 6,000 shares of common stock on August 18, 2026.
Brannin McBee, Chief Development Officer of CoreWeave, Inc. (NASDAQ:CRWV), filed a Statement of Changes in Beneficial Ownership on August 19, 2026, reporting Class A Common Stock conversions and sales that occurred on August 17, 2026.
Brannin McBee, Chief Development Officer of CoreWeave, Inc. (NASDAQ:CRWV), filed a Form 4 on August 19, 2026, disclosing Class B Common Stock conversions and Class A Common Stock sales across three indirect holding entities on August 17, 2026, all executed under a Rule 10b5-1 …
A statement of changes in beneficial ownership filed on August 19, 2026 discloses that Aidan Viggiano, Chief Financial Officer of Twilio Inc (NYSE:TWLO), sold a total of 1,394 shares of Class A Common Stock on August 17, 2026 to satisfy statutory tax withholding obligations …
Director Melvin Sharoky, M.D., filed a Form 4 with the SEC on August 19, 2026, disclosing the sale of 5,000 shares of Insmed Inc common stock on August 17, 2026, through an indirectly held entity.
A Form 4 filed with the SEC on August 18, 2026 discloses that Joel S. Marcus, Executive Chairman and Director of Alexandria Real Estate Equities, Inc. (NYSE:ARE), purchased 5,000 shares of common stock on August 17, 2026.
James Hippel, Chief Financial Officer of BIO-TECHNE Corp (NASDAQ:TECH), filed a Form 4 statement of changes in beneficial ownership on August 19, 2026, reporting transactions dated August 17, 2026.
Kim Kelderman, Chief Executive Officer and Director of BIO-TECHNE Corp, filed a Form 4 on August 19, 2026, reporting the acquisition of two new restricted stock unit grants with an earliest transaction date of August 17, 2026, and disclosing her full holdings of derivative …